IMAGENEBIO INC.

At the H.C. Wainwright conference, ImageneBio presented Olevaprubart as an OX40‑targeted candidate distinguished by receptor targeting, disabled ADCC (no T‑cell depletion) and a long half‑life. The company reports no side effects in ongoing blinded safety assessments comparable to those seen in competing programs and plans measures (patient selection, HHV‑8 screening, close monitoring) to minimize the risk of Kaposi sarcoma. ImageneBio holds $136 million in cash, expected to last into Q1 2028; topline data from the adaptive Phase IIb study in atopic dermatitis are expected in Q4 2025, with alopecia areata data due in 2028. » Más en de.investing.com

ImageneBio shareholders approved a revision of the 2025 Equity Incentive Plan that increases the number of shares issuable by 850,000 and will henceforth include convertible preferred shares and prepaid warrants in the annual automatic increase. At the annual meeting, David P. Bonita and Joseph P. Slattery were elected as Class II directors until the 2029 annual meeting; PricewaterhouseCoopers was reappointed as independent auditor for the fiscal year ending December 31, 2026. The company also entered a securities purchase agreement for a private placement of about $30 million, covering the sale of prepaid warrants for up to 5,770,335 common shares, led by Coastlands Capital with Leerink as placement agent. » Más en de.investing.com

ImageneBio reported for the quarter ended Dec. 31, 2025, earnings per share of $1.27, after -$2.28 in the prior year. For the full year the company posted a loss per share of $9.64, after -$12.24 a year earlier. The quarter shows an improvement year over year, but the annual result remains negative. » Más en finanzen.net